Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands

Publisher: John Wiley & Sons Inc

E-ISSN: 1651-2227|104|9|927-932

ISSN: 0803-5253

Source: ACTA PAEDIATRICA, Vol.104, Iss.9, 2015-09, pp. : 927-932

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content